Effect of dexmedetomidine on diseased coronary vessel diameter and myocardial protection in percutaneous coronary interventional patients.
Ann Card Anaesth
;
2016 July; 19(3): 394-398
Article
Dans Anglais
| IMSEAR
| ID: sea-177422
ABSTRACT
Introduction:
Dexmedetomidine is an alpha‑2 agonist used for conscious sedation. It has also been shown to have a myocardial protective effect in off‑pump coronary artery bypass patients. The aim of the study was to assess the effect of dexmedetomidine for myocardial protection in percutaneous coronary interventional patients.Methodology:
A total of 60 patients (group dexmedetomidine, n = 30 and group normal saline, n = 30) were enrolled in the study. Dexmedetomidine infusion (1 mcg/kg) over 15 min was given as a loading dose after coronary angiography in group dexmedetomidine (D) while normal saline was given in the control group (C) and later maintenance infusion was started at 0.5 mcg/kg/h in both the groups. Coronary vessel diameter was noted before (T0) and after (T1) loading dose of dexmedetomidine/saline in each group. Troponin T (Trop T) values were noted at baseline (T0), 6 h (T2), 12 h (T3) and 24 h (T4) after starting the loading dose. Hemodynamic variables (heart rate [HR] and blood pressure) were monitored at T0, T1, and at regular intervals till 2 h postprocedure.Results:
Coronary vessel diameter and HR significantly decreased in group D as compared to control group (P < 0.05) whereas the decrease in Trop T at 6 h, 12 h, and 24 h were not statistically significant between the two groups.Conclusion:
Dexmedetomidine decreases the coronary vessel diameter, but maintains the myocardial oxygen demand‑supply ratio by decreasing the HR. The decrease in Trop T is statistically insignificant at the doses used.
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
langue:
Anglais
Texte intégral:
Ann Card Anaesth
Année:
2016
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS